Abstract
Background: This study aimed to determine the influence of intraoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) flurbiprofen on postoperative level of programmed death 1 (PD-1) in patients undergoing thoracoscope surgery.
Methods: In this prospective double-blind trial, patients were randomized to receive intralipid (Control group, n=34, 0.1ml/kg, i.v.) or flurbiprofen axetil (Flurbiprofen group, n=34, 1mg/kg, i.v.) before the induction of anesthesia and 6 hours after the initial injection. PD-1 level on T-cell subsets, inflammation and immune markers in peripheral blood were examined before induction of anesthesia (T0), and after surgery (24 hours (T1), 72 hours (T2) and 1 week (T3)). A linear mixed model was used to examine whether the changes from baseline values (T0) between groups were different during our study.
Results: The increases in the percentages of PD-1(+)CD8(+) T-cell observed at T1 and T2 in the control group were higher than in the flurbiprofen group (T1:12.91%±1.65% versus 7.86%±5.71%, P=0.031; T2:11.54%±1.54% versus 8.75%±1.73%, P=0.004) while no difference was observed at T1 and T2 between the groups in terms of change in percentages of PD-1(+)CD4(+) T-cell. Moreover, extensive changes in the percentages of lymphocytes subsets and the concentrations of inflammatory markers was observed at T1 and T2 after surgery, and flurbiprofen seemed to attenuate the most of changes.
Conclusion: Perioperative administration of flurbiprofen attenuated postoperative PD-1 increase on CD8(+) T-cell up to 72 hours, but not after this time. The clinical relevance of changes with PD-1 to long-term outcome of surgery is still unknown.
Trial registration: Chinese Clinical Trail Registry, ChiCTR-IPR-15006482 (date of registration June 2015)
Keywords: Immune cells; Lung cancer; Flurbiprofen; Programmed death 1.
Programmed Death-1 Shapes Memory Phenotype CD8 T Cell Subsets in a Cell-Intrinsic Manner